tyrosine kinase inhibitor Articles
-
Everything You Want to Know About Pharmacophore Model Construction
Structure-based Pharmacophore Molecular docking technology remains the most popular structure-based drug design method, which takes full advantage of protein-ligand interaction information. However, in virtual screening, compared with molecular docking, pharmacophore-based methods have obvious advantages in terms of computational cost and accuracy, and docking-based virtual screening methods ...
-
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly ...
-
Remote Oncology Care: Review of Current Technology and Future Directions
Abstract Cancer patients frequently develop tumor and treatment-related complications, leading to diminished quality of life, shortened survival, and overutilization of emergency department and hospital services. Outpatient oncology treatment has potential to leave cancer patients unmonitored for long periods while at risk of clinical deterioration which has been exaggerated during the COVID19 ...
By Oncodisc
-
Exploring Knowledge Graphs for COVID-19 Drug Discovery
Today, there are only a few therapies approved to treat COVID-19, but while novel therapies can take decades and billions of dollars to develop, are there opportunities to repurpose existing drugs for new therapies? Our latest whitepaper showcases how CAS Knowledge Graphs reveal new connections and insights that identify drugs to potentially repurpose. Drug repurposing is critical for faster ...
-
FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. Statistics show that about 55% of ALK-positive advanced NSCLC patients will develop brain metastases during ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you